Consensus criteria published in 2023 emphasize that a single core attack (such as optic neuritis, myelitis, area-postrema syndrome, or brainstem syndrome) plus a positive AQP4 cell-based assay is sufficient to confirm the diagnosis, provided obvious “red-flag” patterns suggesting another disorder are absent [4]. The gene discussed is AQP4; the disease is myelitis.